Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE-A study

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Atrial fibrillation (AF) patients undergoing coronary stenting often require triple antithrombotic therapy.
• Balancing bleeding risk and ischemic events is crucial in these high-risk patients.
• P2Y12 inhibitors are key in preventing stent thrombosis but increase bleeding complications.

Purpose of the Study:

• To assess if a shortened one-month P2Y12 inhibitor regimen reduces bleeding risk post-coronary stenting in AF patients.
• To determine if this shorter duration increases major adverse cardiovascular events.
• Evaluate the safety of early P2Y12 inhibitor withdrawal in triple antithrombotic therapy.

Main Methods:

• The SAFE-A trial was a randomized controlled trial comparing one-month versus six-month P2Y12 inhibitor therapy.
• Participants received aspirin and apixaban alongside P2Y12 inhibitors.
• Primary endpoint: incidence of any bleeding (TIMI major/minor, BARC grades, transfusion) within 12 months.

Main Results:

• Enrollment was prematurely terminated after 210 patients (target 600) due to slow recruitment.
• No significant difference in the primary bleeding endpoint between one-month and six-month groups (11.8% vs 16.0%; HR 0.70).
• The study lacked sufficient statistical power to detect significant differences.

Conclusions:

• Early termination due to slow enrollment compromised the study's ability to provide definitive conclusions.
• The trial did not achieve adequate statistical power to assess differences in bleeding or cardiovascular events.
• Further research with adequate power is needed to confirm the safety and efficacy of shortened P2Y12 inhibitor therapy in this population.